Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
heard something very similar but we really need to change the narrative here this BP vs Nader is tiring to listen to. All the complaining on this board isnt going to bring BP back. It looks like Nader and BP are fake friends. Im fine with that there is no mudslinging! Leave the mudslinging to AF
Anyone see this article. https://insiderfinancial.com/wading-through-the-stat-news-fud-attack-on-cytodyn-inc-otcmkts-cydy/180253/
AF is such a vile person to say these things. Have to scroll down.
Its an investigational trial correct? This means that they are investigating different approaches. They weren't sure if leronlimab would work as a prophylactic. Now they know its pointless to give the drug unless the cytokines are storming. This is why you wont use it in the phase 3 study if we even have to do one. The FDA should approve this because the safety profile is overwhelming.
Sorry to hear you are so confused but the stock is reacting to the fake news story perpetuated by AF that the trial failed. The trial did not fail. It was quite the success. They met their primary and secondary endpoints. This is AF trying to confuse you by manipulating the stock price. See the news was awesome but you concerned your not reading it correctly. He is a master manipulator. consider yourself manipulated. Watch at the end of the day as buyer on the side scratch their heads and realize that this is an approvable drug with very little downside.
Very frustrated with your analysis. THEY MET THE PRIMARY ENDPOINT! What is your issue?
Primary endpoint shows early clinical improvement in symptom score at Day 3 in patients receiving leronlimab
Clinical improvement assessed by change in total clinical symptom score:
from the press release
Bid in for a million at .0026. Still no Takers. There just arent any sellers so when this thing gets back on expecting this cleanup over the past 6 months will be very beneficial. No one in it wants to sell their shares cheap.
Agree with you that this heads into a super news cycle that details the sales that the company got during the COVID crisis with the JV. Then we can start talking about clinical trial. This is a phase 3 Asset after all. Great position to be in.
What makes you so sure the SEC is investigating. They probably gave them a letter. The company responded. End of story. This idea that this is going to drag on for 5 years is ridiculous. The company will climb back to the pinks. its on the expert market which is the holding grounds for greys to come back.
JUST RELEASED! MORE NEWS - Long lasting PrEP treatment
https://news.ohsu.edu/2020/08/04/new-injection-could-prevent-hiv-in-nonhuman-primates
This software is great. Look at how you can see the $ volume traded. $44 mil today and FACT = 1. Thanks for the analysis.
Final Ingredient - Big Bid - That is all that is missing. It looks like the wall of offers is growing weak as some defect and are going bid or low offer. Either way its weakening the wall.
Wall at .03 starting to weaken. Only 950K shares left to go. not sure why OTCX has so much on the offer is the 445K real or just a blocking offer. if the .03's go this is so ready to pop!
1.4 Price to Sales vs Industry average of 10.3! What are we missing here. Even at .03 this is way way undervalued. Love the piece. It looks like its getting some traction. Hard to figure out why we didnt rise on the news when it came out. I guess people in this stock are thinkers.
Saw that target. Seems completely realistic. Right now we should be tweeting and spreading that article. They really did an excellent job of analysis. Love the deer in the headlight analogy.
if that wall at .03 gets taken down man this flys.
Bullish Research Report Issued! Price Target .08 - .37
https://insiderfinancial.com/fintech-rollup-xalles-otcmkts-xall-shocks-street-with-acquisition-that-doubles-revenues/180210/
Watching it now. Starts out talking about ECA wellness
The oral rinse is the key to this deal. What if it gets COVID approval? Perhaps that is what the speculation is. If it is this stock is so thin it will be $20 before we can blink.
Dont forget new name change 27 Health Holdings Corp!
Only 280K shares in the real float. so when it trade 70K shares or 25% of the float in one day something is happening. Anyone that says EWLL - nope - dont thing so.
Market cap of $2.5 million is just too too low. They get an order for the oral rinse I see that being a 5.0 mil order. Then what about reorders. Now we have a 20 - 30 million company in revs. Give it no multiple. 1.3 million O/S means it could be a $30+ stock easy!
Thats cool that you didnt sell but did you buy down when it was in the dumps? You over seven figures in share count?
NEW TWEET!
$XALL 2020 Acquisition Recap - 4 acquisitions completed: Gateway Innovations, MinervaWorks, Intel365, Argus Technology Partners. 1 announced/closing soon: 1Rivet Global. 4 in negotiations with potential July signing dates and August closing dates. More to come. #fintech, #XALL
— Xalles (@xalles1) July 9, 2020
there are good looking charts. there are great looking charts.
XALL is perfection. So Agree with your analysis. Imagine breaking that wall at .018 Whats the next stop?
COMMENTATORS NEEDED - Anyone going to defend that new article? Chuckles the Short is interfering on the comments.
https://talkmarkets.com/content/stocks--equities/hiv-cure-challenger-cytodyn-takes-on-the-gilead-sciences?post=267711
OFFICIAL PRESS RELEASE - Just out
https://www.cytodyn.com/newsroom/press-releases/detail/443/cytodyns-ceo-dr-pourhassan-to-appear-on-drbeen-webcast
I saw a tweet but this makes it official. Its on!
Huge audience - This could blow things up for next week.
HIV CURE Article! Just Posted
https://talkmarkets.com/content/stocks--equities/hiv-cure-challenger-cytodyn-takes-on-the-gilead-sciences?post=267711
We need to be talking about this. This is really big news that just got swept under the rug because of the Citron thing.
HIV CURE
NASH
CANCER
COVID-19
HIV MONOTHERAPY
MS
Seriously this is a big pharma company! All with one drug. I think we can be bigger than Merck!
You are so off the mark on your characterization to the upside. It was fueled by speculation that the drug actually works. News flash it does work. I read through this article. It absolutely nails it.
https://insiderfinancial.com/cytodyn-otcmkts-cydy-bolts-higher-on-mexican-approval-chatter/180087/
They do a best case worst case scenario. No matter how you look at it. CYDY is an approvable drug and will not only beat the endpoint. It looks like a crushing is coming. Most people get
ANECTDOTAL PEOPLE DONT COME OFF LIFE SUPPORT!
Dr Been Talking Leronlimab - LIVE NOW!
Theres evidence right here
https://emerginggrowth.com/misleading-headline-on-cydodyn-cydy-triggers-algo-selling/
Look at the first image. They clearly have it.
Proactive VIDEO out. https://www.proactiveinvestors.com/companies/news/923234/cytodyn-ceo-calls-citron-research-report--false--updates-on-coronavirus-clinical-trials-923234.html
If you refresh your cache it will disappear. get the 404 msg
MASSIVE LONG ARTICLE TO CIRCULATE JUST OUT - Addresses shorts! Spread it around. Mexican approval. Look at the analysis. This drug is totally approvable!
https://insiderfinancial.com/cytodyn-otcmkts-cydy-bolts-higher-on-mexican-approval-chatter/180087/
This confusion of the tcells is called T-Cell Anergy. What happens is that the virus used intracellular galectin-3 to bud the virus. When the cell evntually burst to release the virion the Galectin-3 forms a plaque on the T-cell which prevents the CD-8 cell from killing.
https://www.microbiologyresearch.org/docserver/fulltext/jgv/100/3/333_vir001208.pdf?expires=1593368131&id=id&accname=guest&checksum=6D439448972325A8EF9FD002E697A764
https://www.pnas.org/content/115/19/E4396/tab-figures-data
Love this DD Amanda chart - clearly money is flowing into it. Nice to see the social media is in the top chatter boards. I think the dollar volume traded is significant. People must be exercising their warrants bringing funds into the company. this will lead to that uplisting.
Exactly - A REAL COMPANY with real revenues! Great find. this is a really good space.
Bought $8 mil of revenue for $250,000 of restricted stock! Great deal.
CLIVEMAUND.com STRONG BUY Rating - Aid and COVID-19 stock on verge of starting another powerful upleg.
Cytodyn is a stock that is in an ongoing powerful bullmarket, which is not surprising considering the news coming out of the company. Dates for the commercial sale of their proprietary leronlimab drug for use against HIV and possibly for emergency use against COVID -19 are expected to be announced soon and also other news, and the stock is expected to uplist to the NYSE or NASDAQ.
Some of you may recall that we made a quick 53% gain in this stock in a week back in April when we took profits largely because it had become so overbought, and we resolved to stand aside and await developments. It is somewhat remarkable that we made that gain at a time when the stock was already in consolidation mode following a steep 2nd upwave in March as we can see on its latest 7 month chart.
Speculating on your question. It seems it was possible that out of the hundreds of people that were dosed that one person might have had Alzheimers? If they did and got leronlimab and the doctor saw an improvement then perhaps that is what motivated him to make such a bold move. There is evidence of the trafficking of immune cells in Alzheimers. so the theory is there and possibly the patient gave them an anectdotal sign.
Dont see why it wont run today. Just one big bid - all the selling is sucked up by long term buyers. So respectfully disagree. Think this starts a breakout.
This think technically looks like a monster. It just needs a little catalyst. only 300K of the offer right now. Imagine if there was news soon. It would tip the scales higher. Love to see a breakout.
I believe you are correct. They were a video game company and what they needed was more users to launch. So that is what led them to the top up opportunity with many users available to try to sell video games but it morphed into obviously a telecom portal company that manages the telecom portals and the other ecommerce portals for PDD, JD, and BABA's Tmall
https://www.otcmarkets.com/stock/FNGR/news/China-Unicoms-Yunnan-Subsidiary-Awards-an-Agreement-to-FingerMotion-Inc-to-Manage-and-Operate-its-Online-Flagship-Stores?id=234045
Here's the press release.
JiuGe will be operating and managing China Unicom's Yunnan Subsidiary's existing online flagship stores in three major e-commerce platforms in China, namely Tmall (operated by Alibaba (BABA), JD.com (JD) and PinDuoDuo (PDD). According to a June 2018 article by Forbes titled 'For Brands, Alibaba is The Gateway to China and Chinese Customers', Forbes stated that Alibaba has 617 million monthly mobile users and 552 million active users on its China retail marketplaces (Tmall and Taobao). In comparison, according to Tech in Asia, JD.com has 292 million customers.
They also do SMS
Thks for reply- I ran out to time to respond to your question during happy hour so I have to wait until next week, but I know where the answer is.
This is an old but a good article on $CYDY - very insightful - I think you will find what you are looking for.
https://seekingalpha.com/article/4187810-gileads-hiv-franchise-under-assault-stares-down-paradigm-changing-drug
Did you see the article recapped it too. https://emerginggrowth.com/adam-feuersteins-fishing-expedition-on-cytodyn-cydy-continues-to-cast-an-empty-net/
Article today on CYDY https://emerginggrowth.com/adam-feuersteins-fishing-expedition-on-cytodyn-cydy-continues-to-cast-an-empty-net/ Looks like AF got his head handed to him.